Sold as Eulexin. Every FDA application for this active ingredient: 1 branded and 5 generic.
As of Nov 13, 2026, FDA lists 6 applications for Flutamide (sold as Eulexin), first approved Jan 27, 1989, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Eulexin | Part D | $153K | -5% | 0 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jan 27, 1989 | EulexinNDA 18554 ยท New molecular entity | Schering | 21 | Discontinued |
| Sep 18, 2001 | FlutamideANDA 75298 | Waylis Therap | 1 | Marketed |
| Sep 18, 2001 | FlutamideANDA 75818 | Chartwell Rx | 3 | Discontinued |
| Sep 18, 2001 | FlutamideANDA 75820 | Actavis Labs Fl Inc | 1 | Discontinued |
| Sep 19, 2001 | FlutamideANDA 75780 | Cipla | 1 | Discontinued |
| May 9, 2003 | FlutamideANDA 76224 | Pharmobedient | 1 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA
Cipla